1. 2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC). (September 2015) Authors: Hurwitz, H.; Zafar, Y.; Kozloff, M.; Hubbard, J.; Van Cutsem, E.; Bennouna, J.; Arnold, D.; Bekaii-Saab, T.; Srock, S.; Revil, C.; Fish, S.; Barue, V.; Grothey, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗